- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05420532
Designing Virtual Reality-based Software for People With Multiple Sclerosis
Designing Virtual Reality-based Testing and Rehabilitation for Upper Extremity Software for People With Multiple Sclerosis
Study Overview
Detailed Description
Multiple sclerosis (MS) is a chronic, inflammatory, and demyelinating disorder that requires long-term rehabilitation. Numerous systematic reviews on MS have demonstrated the effectiveness of rehabilitation strategies such as exercise training, physical therapy, occupational therapy, and multidisciplinary therapy. However, despite the importance of upper extremity performance in daily functional activities, rehabilitation of people with MS (pwMS) generally focuses more on gait and balance, and upper extremity problems remain in the background.
In addition, rehabilitation treatments for pwMS are described as very long and systematic, leading to loss of motivation and adjustment. As a result, technology-based rehabilitation systems such as virtual reality (VR) have been promising in recent years and can provide person-centered task-oriented rehabilitation without needing a device or controller.
In pwMS, physiotherapy and rehabilitation programs based on today's VR studies are usually prepared with game software for computer users without physical disabilities. However, the number of these studies based solely on classical game software has a limited place in treating patients today and is considered insufficient. Moreover, this software is complicated for patients, has a fast-paced structure, and fails to provide disability-focused education or meet patient needs.
For this reason, it is necessary to develop specific game software for pwMS. The study aims to develop virtual reality exergame software for upper extremity rehabilitation in pwMS and evaluate the usability.
Persons who are followed by the outpatient Multiple Sclerosis Clinic of Dokuz Eylül University Hospital will participate in the study. Fifteen participants will be included to determine the feasibility of the software, and they will experience the system for one session. Then 15 participants will be included to investigate the effects of software on upper extremity functions during 8 weeks.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Serkan Ozakbas, MD
- Phone Number: 0232 412 4964
- Email: serkan.ozakbas@gmail.com
Study Contact Backup
- Name: Asiye Tuba Ozdogar, Research Assisstant
Study Locations
-
-
-
İzmir, Turkey
- Recruiting
- Dokuz Eylul University
-
Contact:
- Serkan Ozakbas, MD
- Phone Number: 0232 412 4964
- Email: serkan.ozakbas@gmail.com
-
Sub-Investigator:
- Cavid Baba, MD
-
Sub-Investigator:
- Seda Dastan, BSc
-
Sub-Investigator:
- Hilal Karakaş, BSc
-
Contact:
- Asiye Tuba Ozdogar, MSc
-
Sub-Investigator:
- Turhan Kahraman, Assoc Prof, PhD
-
Principal Investigator:
- Asiye Tuba Ozdogar, PhD
-
Sub-Investigator:
- Ergi Kaya, MD
-
Sub-Investigator:
- Mehmet Hilal Ozcanhan, Assoc. Prof.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Having a definitive diagnosis of MS according to the 2017 McDonald criteria
- Being over 18 years old
- To be willing to participate in the study.
Exclusion Criteria:
- Having a neurological disease other than MS
- Cognitive disability at a level that hinders assessment and treatment.
- Having a relapse 30 days before or during the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Exergaming Group
A video game-based physical activity training will be applied under a physiotherapist supervision for 1 days/week for 8 weeks.
|
A video game-based physical activity training applied using a commercial game console.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nine-Hole Peg Test
Time Frame: Change from Baseline at 8 weeks
|
The Nine-Hole Peg Test is used to assess manual dexterity performance.
It requires participants to repeatedly place and then remove nine pegs into nine holes, one at a time, as quickly as possible.
Two trials for each hand are performed and the score is the average time.
Higher scores indicate less manual dexterity performance.
|
Change from Baseline at 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Jamar Hand Dynamometer
Time Frame: Change from Baseline at 8 weeks
|
The Jamar Hand Dynamometer will be used to measure isometric force and peak strength.
|
Change from Baseline at 8 weeks
|
Arm Function in Multiple Sclerosis Questionnaire
Time Frame: Change from Baseline at 8 weeks
|
Arm Function in Multiple Sclerosis Questionnaire is a unidimensional 31-item questionnaire for measuring arm function in MS.
The total sum score ranged from 31 to 186 and a high score indicates a low degree of arm function.
|
Change from Baseline at 8 weeks
|
The User Satisfaction Evaluation Questionnaire
Time Frame: immediately after the session
|
The User Satisfaction Evaluation Questionnaire, consisting of six questions, will be used to assess the user's satisfaction with the system and exergaming.
|
immediately after the session
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Expanded Disability Status Scale
Time Frame: At baseline
|
The Expanded Disability Status Scale is a method of quantifying disability in multiple sclerosis.
The scale is based on a neurological examination by a clinician.
It has steps from 0 to 10.
The higher scores indicate higher neurological disability.
|
At baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022/14-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Exergaming
-
Riphah International UniversityCompleted
-
Teesside UniversityCompletedMusculoskeletal Pain | Musculoskeletal Pain DisorderUnited Kingdom
-
Riphah International UniversityRecruiting
-
Norwegian University of Science and TechnologyTerminated
-
Norwegian University of Science and TechnologyCompleted
-
King Saud UniversityCompletedFatigue | Childhood ALLSaudi Arabia
-
University Rehabilitation Institute, Republic of...Jozef Stefan InstituteCompletedParkinson DiseaseSlovenia
-
Charles Drew University of Medicine and ScienceWithdrawn
-
Pennington Biomedical Research CenterAmerican Heart AssociationCompletedChildhood ObesityUnited States
-
Dokuz Eylul UniversityCompleted